Scholar Rock pens $1.5bn deal with Gilead
Gilead Sciences Inc. and Scholar Rock Holding Corp. partnered to develop inhibitors of transforming growth factor beta activation for fibrotic diseases.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.